Based on extensive review of the literature, it appears that the development of an optimal treatment strategy for each patient with T2DM, as well as for those with prediabetes, will require an accurate early diagnostic assessment of the degree of residual BCF within the context of each individual’s insulin resistance. The gene discussed is INS; the disease is type 2 diabetes mellitus.